Navigation Links
MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Date:9/24/2007

GAITHERSBURG, Md., Sept. 24 /PRNewswire/ -- MedImmune, Inc. announced today that it has licensed its proprietary reverse genetics intellectual property to GlaxoSmithKline to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated from segments of DNA. For potential pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only with segments of the virus's genome.

"MedImmune is pleased to enter into a fourth agreement to license our reverse genetics technology to manufacturers," said Jonathan Klein-Evans, J.D., MedImmune's vice president, intellectual property. "Making this important technology available to the vaccine development team at GlaxoSmithKline and their peers at other companies may have a significant positive impact on the manufacturing of influenza vaccines due to the efficiency and reliability of the process."

MedImmune will receive an upfront payment and has the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates because it allows them to avoid working directly with the infectious, circulating pandemic strains. As the owner or exclusive licensee of key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune remains committed to making sure that the technology is accessible to government institutions and industry manufacturers. As such, the company has offered other influenza vaccine manufacturers non-exclusive licenses to this intellectual property estate for use in manufacturing seasonal or pandemic vaccines.

Since December of 2006, MedImmune has licensed its reverse genetics technology to CSL Limited of Australia, sanofi pasteur and Novartis.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L) (NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. US Government Licenses New Hypertension Drug
2. Panacea Biotec In-Licenses FMD Vaccine
3. Thailand Goes Ahead With Licenses for Generic Drugs
4. Swedish Biotech Licenses HIV Drug to China for Development
5. More Foreign Trained Doctors Receive Licenses
6. FDA Licenses First US Vaccine Against Avian Flu
7. Thailand Will Not Issue Compulsory Licenses for Patented Drugs
8. Vitamin C reverses pre eclampsia
9. Creams may not reverse aging
10. Researchers reversed the process of memory loss
11. Faster way of producing Bird flu vaccine using Reverse Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ ... during the summer of 2016. The program was made possible by a Pennsylvania ... Department of Health and Human Services Administration. The broadcast, Use Your Head: ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce ... service for Texas, they are expanding their presence in Dallas. One of the most ... will bring new jobs to the Dallas and Forth Worth market. STAT takes pride ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has been recognized ... Top Workplaces National Standard. To learn more about ... ... Inc.) ... survey administered by WorkplaceDynamics, LLC, a research firm specializing in organizational ...
Breaking Medicine Technology: